Estrogen patch shortage prompts doctors, lawmakers to seek FDA action
Categories: health
Quick Summary
The US Food and Drug Administration (FDA) has announced a shortage of estrogen patches, which are commonly used for hormone replacement therapy to alleviate menopausal symptoms. This shortage is attributed to manufacturing issues and affects several brands of estrogen patches, prompting concerns among patients who rely on these medications.
Key Points
- The FDA has declared a shortage of estrogen patches due to manufacturing issues
- The shortage affects several brands, including Minivelle, Vivelle-Dot, and Climara
- Estrogen patches are used for hormone replacement therapy, particularly for menopausal symptoms
- Patients are advised to consult their healthcare providers for alternative treatment options
View Original Article
This summary is AI generated and may be inaccurate